NBIX Neurocrine Biosciences Inc

For the fiscal year ended 31/12/2022: Neurocrine Biosciences Inc's revenues increased by 31.34% and amounted to 1.49B. Net income increased by 72.43% to 154.50M. Net assets increased by 24.29% to 1.71B and EPS increased from 0.92 to 1.56.